Aptevo Therapeutics

Aptevo Therapeutics

  • Founded: 2016
  • Location: Seattle, WA
  • Employee range: 50 - 200
  • Clinical stage: Clin1b
  • Therapy area: AML/MDS
  • Drug types: ONC
  • Lead product: APVO436
  • Product link: https://aptevotherapeutics.com/pipeline/
  • Funding: $5M stock Aug 2023; $9.6M stock Mar 2023; $22M stock Mar 2019



job board

Short description:

Oncology and hematology therapeutics

Drug notes:

ALG.APV-527 Clin0 solid tumors; APVO603 Clin0 solid tumors; APVO442 RD/Clin0 prostate cancer; APVO711 RD/Clin0 solid tumors

Long description:

Aptevo Therapeutics is developing novel therapeutics for oncology and hematology. The immune system, including T cells, play an important role in the detection and killing of tumor cells, but is often suppressed by the tumor itself. Using their proprietary modular protein technology platform, ADAPTIR, Aptevo is designing both mono- and bispecific protein therapeutics to redirect T cells to kill tumor cells. Aptevo’s lead candidate, APVO436, is a bispecific candidate that is designed to redirect CD3-expressing T cells to kill CD123-positive tumors for treatment of acute myeloid leukemia. Apetvo has also built their ADAPTIR-FLEX platform, which expands upon ADAPTIR by enabling the design of protein therapeutics with multivalent binding to improve specificity and potency.


Aptevo Therapeutics
Senior Accountant, Clinical Projects
Seattle, WA, US|41 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com